ArticleApplied and environmental microbiology2014
Inhibition of biofilm formation by T7 bacteriophages producing quorum-quenching enzymes.
Article in Applied and environmental microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
106 citing papers in PubMed, 206 citations in OpenAlex.
- Escherichia coli bacteriophage vB_EcoS_MS2 effectively prevents biofilm formation but shows limited activity against mature biofilms.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Article
- Quorum-quenching enzymes as next-generation antibiofilm therapeutics: mechanisms, applications, and future perspectives.World journal of microbiology & biotechnology · 2026Review
- Bacteriophage therapy for antimicrobial-resistant, biofilm‑associated diabetic foot infection: delivery routes, phage antibiotic synergy, and practical wound‑care integration.Archives of microbiology · 2026Review
- Bacteriophages as Antibacterial Agents Against Bovine Pathobionts Associated with Foodborne Human Morbidity.Viruses · 2026Review
- Phages and quorum sensing: findings to consider in phage therapy.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- Nanoengineered γ MnOLife (Basel, Switzerland) · 2026Article
- Isolation and phenotypic characterization of a lytic bacteriophage with quantitative host range and antibiofilm activity against clinical MRSA isolates.Biotechnology notes (Amsterdam, Netherlands) · 2026Article
- Sanitization of food-grade materials: Combined effect of an enzymatic product and two chemical sanitizers onAIMS microbiology · 2026Article
- Domain antibody-displayed phages as a novel biofilm-targeted therapy for Staphylococcus aureus.International microbiology : the official journal of the Spanish Society for Microbiology · 2025Article
- Effect of Chemical Sanitizers Alone or Combined with An Enzymatic Product Against Pseudomonas fluorescens Biofilms on Food-Grade Materials.Current microbiology · 2025Article
- Synergistic Disruption of Foodborne Pathogen Biofilms by Oregano Essential Oil and Bacteriophage phiLLS: Atomic Force Microscopy Insights.Molecules (Basel, Switzerland) · 2025Article
- Characterization, Genomic Analysis and Application of Five Lytic Phages Against Carbapenem-ResistantMicroorganisms · 2025Article
- CombattingAntibiotics (Basel, Switzerland) · 2025Review
- Isolation and Genomic Analysis ofAntibiotics (Basel, Switzerland) · 2025Article
- Facing Foodborne Pathogen Biofilms with Green Antimicrobial Agents: One Health Approach.Molecules (Basel, Switzerland) · 2025Review
- Isolation and characterization of fMGyn-Pae01, a phiKZ-like jumbo phage infecting Pseudomonas aeruginosa.Virology journal · 2025Article
- Engineering bacteriophages for targeted superbug eradication.Molecular biology reports · 2025Review
- Understanding phage BX-1 resistance inMicrobiology spectrum · 2025Article
- Engineering Phages to Fight Multidrug-Resistant Bacteria.Chemical reviews · 2025Review
46 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial growth in biofilms is the major cause of recalcitrant biofouling in industrial processes and of persistent infections in clinical settings. The use of bacteriophage treatment to lyse bacteria in biofilms has attracted growing interest. In particular, many natural or engineered phages produce depolymerases to degrade polysaccharides in the biofilm matrix and allow access to host bacteria. However, the phage-produced depolymerases are highly specific for only the host-derived polysaccharides and may have limited effects on natural multispecies biofilms. In this study, an engineered T7 bacteriophage was constructed to encode a lactonase enzyme with broad-range activity for quenching of quorum sensing, a form of bacterial cell-cell communication via small chemical molecules (acyl homoserine lactones [AHLs]) that is necessary for biofilm formation. Our results demonstrated that the engineered T7 phage expressed the AiiA lactonase to effectively degrade AHLs from many bacteria. Addition of the engineered T7 phage to mixed-species biofilms containing Pseudomonas aeruginosa and Escherichia coli resulted in inhibition of biofilm formation. Such quorum-quenching phages that can lyse host bacteria and express quorum-quenching enzymes to affect diverse bacteria in biofilm communities may become novel antifouling and antibiofilm agents in industrial and clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.